Because they are considered more tolerable, safer in overdose, less likely to generate extrapyramidal side effects(EPS) or contribute to treatment-emergent tardive dyskinesia (TD). Atypicals are known to have a more predictable and benign side effect profile when compared to traditional or typical antipsychotics (Verdoux et al,2010). As a rule, typical antipsychotic agents carry considerable liability because of their association with high rates of EPS and their subsequent increased risk for the development of TD over tome, which may not be reversible (Sikich et al., 2008;Mattai et al., 2010; Verdoux et al., 2010). There are currently no published randomized, placebo-controlled studies that have evaluated the utility of typical antipsychotics as adjunct therapy in MMD patients.